The Schall Law Firm announced a class action lawsuit against REGENXBIO Inc. for allegedly making false and misleading statements about its drug candidate RGX-111. The company is accused of hiding negative safety and efficacy data, including the discovery of a CNS tumor in a trial participant. Investors who bought REGENXBIO securities between February 2022 and January 2026 may have suffered losses and are encouraged to join the lawsuit by April 14, 2026. The case is not yet certified, so investors are not yet represented by an attorney but can participate as absent class members if they take no action.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
